Thought Leadership

Latest Report

Obesity matters for drug developers

Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%.  The R&D pipeline is filling up as more and more companies try to grab a slice of this…

Report library

Thumbnail

EvaluatePharma Orphan Drug Report 2019

$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…

Thumbnail

Vantage 2019 Preview

2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…